Comparison of Stroke Care Costs in Urban and Nonurban Hospitals and Its Association With Outcomes in New Zealand: A Nationwide Economic Evaluation.


Journal

Stroke
ISSN: 1524-4628
Titre abrégé: Stroke
Pays: United States
ID NLM: 0235266

Informations de publication

Date de publication:
03 2023
Historique:
entrez: 27 2 2023
pubmed: 28 2 2023
medline: 3 3 2023
Statut: ppublish

Résumé

Although geographical differences in treatment and outcomes after stroke have been described, we lack evidence on differences in the costs of treatment between urban and nonurban regions. Additionally, it is unclear whether greater costs in one setting are justified given the outcomes achieved. We aimed to compare costs and quality-adjusted life years in people with stroke admitted to urban and nonurban hospitals in New Zealand. Observational study of patients with stroke admitted to the 28 New Zealand acute stroke hospitals (10 in urban areas) recruited between May and October 2018. Data were collected up to 12 months poststroke including treatments in hospital, inpatient rehabilitation, other health service utilization, aged residential care, productivity, and health-related quality of life. Costs in New Zealand dollars were estimated from a societal perspective and assigned to the initial hospital that patients presented to. Unit prices for 2018 were obtained from government and hospital sources. Multivariable regression analyses were conducted when assessing differences between groups. Of 1510 patients (median age 78 years, 48% female), 607 presented to nonurban and 903 to urban hospitals. Mean hospital costs were greater in urban than nonurban hospitals ($13 191 versus $11 635, Better outcomes following initial presentation to urban hospitals were associated with greater costs compared to nonurban hospitals. These findings may inform greater targeted expenditure in some nonurban hospitals to improve access to treatment and optimize outcomes.

Sections du résumé

BACKGROUND
Although geographical differences in treatment and outcomes after stroke have been described, we lack evidence on differences in the costs of treatment between urban and nonurban regions. Additionally, it is unclear whether greater costs in one setting are justified given the outcomes achieved. We aimed to compare costs and quality-adjusted life years in people with stroke admitted to urban and nonurban hospitals in New Zealand.
METHODS
Observational study of patients with stroke admitted to the 28 New Zealand acute stroke hospitals (10 in urban areas) recruited between May and October 2018. Data were collected up to 12 months poststroke including treatments in hospital, inpatient rehabilitation, other health service utilization, aged residential care, productivity, and health-related quality of life. Costs in New Zealand dollars were estimated from a societal perspective and assigned to the initial hospital that patients presented to. Unit prices for 2018 were obtained from government and hospital sources. Multivariable regression analyses were conducted when assessing differences between groups.
RESULTS
Of 1510 patients (median age 78 years, 48% female), 607 presented to nonurban and 903 to urban hospitals. Mean hospital costs were greater in urban than nonurban hospitals ($13 191 versus $11 635,
CONCLUSIONS
Better outcomes following initial presentation to urban hospitals were associated with greater costs compared to nonurban hospitals. These findings may inform greater targeted expenditure in some nonurban hospitals to improve access to treatment and optimize outcomes.

Identifiants

pubmed: 36848424
doi: 10.1161/STROKEAHA.122.040869
doi:

Types de publication

Observational Study Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

848-856

Auteurs

Joosup Kim (J)

Stroke and Ageing Research, Department of Medicine, School of Clinical Sciences at Monash Health, Department of Medicine, Monash University, Clayton, Australia (J.K., D.A.C.).
Stroke Division, Florey Institute of Neuroscience and Mental Health, University of Melbourne, Heidelberg, Australia (J.K., D.A.C.).

Dominique A Cadilhac (DA)

Stroke and Ageing Research, Department of Medicine, School of Clinical Sciences at Monash Health, Department of Medicine, Monash University, Clayton, Australia (J.K., D.A.C.).
Stroke Division, Florey Institute of Neuroscience and Mental Health, University of Melbourne, Heidelberg, Australia (J.K., D.A.C.).

Stephanie Thompson (S)

Department of Medicine, University of Otago, Wellington, New Zealand (S.T., W.L., A.R.).

John Gommans (J)

Department of Medicine, Hawkes's Bay Hospital, Hastings, New Zealand (J. Gommans).

Alan Davis (A)

Department of Medicine, Whangarei Hospital, New Zealand (A.D.).

P Alan Barber (PA)

Department of Medicine, University of Auckland, New Zealand (P.A.B.).

John Fink (J)

Department of Neurology, Christchurch Hospital, New Zealand (J.F.).

Matire Harwood (M)

Department of General Practice and Primary Healthcare, University of Auckland, New Zealand (M.H.).

William Levack (W)

Department of Medicine, University of Otago, Wellington, New Zealand (S.T., W.L., A.R.).

Harry McNaughton (H)

Medical Research Institute of New Zealand, Wellington, New Zealand (H.M.).

Virginia Abernethy (V)

Stroke Foundation of New Zealand, Wellington, New Zealand (V.A.).

Jacqueline Girvan (J)

Ashburton, New Zealand (J. Girvan).

Valery Feigin (V)

National Institute for Stroke and Applied Neurosciences, Auckland University of Technology, New Zealand (V.F.).

Hayley Denison (H)

Research Centre for Hauora and Health, Massey University, Wellington, New Zealand (H.D., M.C., J.D.).

Marine Corbin (M)

Research Centre for Hauora and Health, Massey University, Wellington, New Zealand (H.D., M.C., J.D.).

Andrew Wilson (A)

Department of Medicine, Wairau Hospital, Blenheim, New Zealand (A.W.).

Jeroen Douwes (J)

Research Centre for Hauora and Health, Massey University, Wellington, New Zealand (H.D., M.C., J.D.).

Anna Ranta (A)

Department of Medicine, University of Otago, Wellington, New Zealand (S.T., W.L., A.R.).
Department of Neurology, Wellington Hospital, New Zealand (A.R.).

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH